Agenus said its Q3 2026 update was marked by progress toward starting Phase 3 trials for its ROBBIN program. The company also cited new NEST and UNICORN data, f

Agenus said its Q3 2026 update was marked by progress toward starting Phase 3 trials for its ROBBIN program. The company also cited new NEST and UNICORN data, first BOT+BAL approvals in Armenia, and earlier Phase 2 dMMR colon cancer response rates of 72% pCR and 83% MPR.